BRCA1 and prostate cancer: Interestingly, several teams report different clinical cases involving breast (55, 56), ovarian (35, 57), pancreatic (58), and prostate cancers (59), highlighting that PARPi resistance mechanisms would be shared between cancers of the BRCA1/2 spectrum.